ALX flunks its gastric test
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
AACR 2024 – Akeso impresses in stomach cancer
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
